Dexamethasone

Neurology Cerebral oedema caused by brain tumours, neurosurgery, bacterial meningitis, brain abscess. Pulmonary and respiratory diseases Severe acute asthma attack. Dermatology Oral initial treatment of extensive, severe, acute skin diseases that respond to glucocorticoids, such as erythroderma, pemphigus, vulgaris, acute eczema.

Autoimmune disorders/rheumatology Oral initial treatment of autoimmune diseases, such as systemic lupus erythematosus (especially visceral forms). g. rapidly destructive forms and/or with extra-articular manifestations. g. tuberculosis, typhoid) only with concomitant anti-infective therapy.

Oncology Palliative treatment of malignant tumours. Endocrinology Congenital adrenogenital syndrome in adulthood.

INDICATIONS AND USAGE A l l ergic States:

Control of severe or incapacitating a llergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness.

Dermatologic Diseases:

Bul l ous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome).

Endocrine Disorders:

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis.

MAXIDEX® (dexamethasone ophthalmic ointment, USP and dexamethasone ophthalmic suspension, BP) is indicated for: • Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, iritis, cyclitis, and selected infective conjunctivitis when the inherit hazard of steroid use is acceptable to obtain an advisable diminution in edema and inflammation.

• Corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. 1 Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of MAXIDEX in children have not been established. 2 Geriatrics Geriatrics (> 60 years of age): No overall differences in safety or effectiveness have been observed between elderly and younger patients.

1) • inflammation of the posterior segment of the eye presenting as non-infectious uveitis